|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Moreover, the treatment for advanced EGFR-positive NSCLC might be different between 19 Del and 21 L858R.
|
26933807 |
2016 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails due to the emergence of T790M mutation.
|
29568384 |
2018 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The most common NSCLC-associated EGFR mutations are deletions in exon 19 and L858R mutation in exon 21, together accounting for 90% of EGFR mutations.
|
19366827 |
2009 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Secondary acquired mutant EGFR (L858R-T790M) overexpressed NSCLC forms one of the prevalent form of resistant NSCLC.
|
31078412 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
|
30030903 |
2018 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Two main categories of epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) patients are deletions in exon 19 and L858R in exon 21.
|
31327643 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Seven of these mutations were novel, and one was the L858R mutation described in non-small-cell lung cancer.
|
18998063 |
2009 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva, Astellas Pharma Inc., Northbrook, IL, http://www.us.astellas.com/) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
|
24868098 |
2014 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Exon 19 deletion mutations and the single-point substitution mutation L858R in exon 21 are the most frequent in NSCLC and are termed 'classical' mutations.
|
19680293 |
2009 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The EURTAC trial demonstrated the greater efficacy of erlotinib compared with chemotherapy for the first-line treatment of European patients with advanced non-small-cell lung cancer (NSCLC) harboring oncogenic epidermal growth factor receptor (EGFR) mutations (exon 19 deletion or L858R mutation in exon 21) in tumor tissue.
|
26181014 |
2015 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Therefore, a meta-analysis was performed to assess the efficacy of icotinib in NSCLC patients harboring EGFR mutations (19Del or L858R) and wild type (19Del and L858R loci wild type).
|
28430623 |
2017 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer.
|
28357677 |
2017 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Together, exon 19 deletion and exon 21 L858R gene substitution are present in about 10% of Caucasian patients and 20-40% of Asian patients with non-small cell lung cancer.
|
25855240 |
2016 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
To establish a testing algorithm for EGFR mutation status in NSCLC patients, we utilized the peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp assay to determine the EGFR mutation, and immunostaining to detect the delE746-A750 and L858R mutation protein.
|
22858448 |
2012 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We were able to identify EGFR mutations in NSCLC effusion and CSF with a sensitivity of 100% (5/5) using the anti-delE746-A750 antibody and 100% (8/8) using the anti-L858R antibody.
|
21444121 |
2011 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Mutations of the epidermal growth factor receptor (EGFR), particularly deletional mutations (DEL) in exon 19 and L858R in exon 21, are reportedly correlated with clinical outcome in patients with non-small cell lung cancer (NSCLC) receiving the EGFR tyrosine kinase inhibitors gefitinib and erlotinib, suggesting that detection of EGFR mutations would have an important role in clinical decision making.
|
16938658 |
2006 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Targeting the 3 most common epidermal growth factor receptor mutations (exon 19 deletion, T790M, L858R) found in non-small cell lung cancer (NSCLC), we achieved >20-fold increases in AF and detected mutations by use of qPCR at an AF of 0.1%.
|
29038154 |
2018 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We retrospectively analyzed a cohort of 100 patients with stage IIIB/IV NSCLC screened for two major EGFR mutations (exon 19 deletions and L858R mutation).
|
19777258 |
2010 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) patients carrying specific EGFR kinase activating mutations (L858R, delE746-A750) respond well to tyrosine kinase inhibitors (TKIs).
|
27612423 |
2016 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
On September 27, 2018, the United States Food and Drug Administration (FDA) approved dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
|
31050691 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The most common mutations (L858R and exon 19 deletions) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum-based chemotherapy in patients with advanced NSCLC.
|
22119437 |
2012 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) who either (1) had a new diagnosis and were planned for initial therapy or (2) had developed acquired resistance to an EGFR kinase inhibitor and were planned for rebiopsy underwent initial blood sampling and immediate plasma ddPCR for EGFR exon 19 del, L858R, T790M, and/or KRAS G12X between July 3, 2014, and June 30, 2015, at a National Cancer Institute-designated comprehensive cancer center.
|
27055085 |
2016 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
First generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (gefitinib and erlotinib) demonstrate excellent clinical efficacy for NSCLC patients carrying EGFR oncogenic mutations (L858R, del exon 19 deletions between amino acids 746 and 750).
|
26968253 |
2016 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The antiproliferative activity of a dual PI3K/mTOR inhibitor BEZ235 was examined by the WST-1 assay and the soft agar colony-formation assay in 2 normal cell lines and 12 NSCLC cell lines: 6 expressing wild-type EGFR and 6 expressing EGFR with activating mutations, including exon 19 deletions, and L858R and T790 M point mutations.
|
31262325 |
2019 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).
|
29151359 |
2018 |